{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T16:48:16Z","timestamp":1776962896264,"version":"3.51.4"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.27909","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T02:52:30Z","timestamp":1607482350000},"page":"e2027909","source":"Crossref","is-referenced-by-count":33,"title":["Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia"],"prefix":"10.1001","volume":"3","author":[{"given":"Gesche","family":"J\u00fcrgens","sequence":"first","affiliation":[{"name":"Clinical Pharmacological Unit, Zealand University Hospital, Roskilde, Denmark"},{"name":"Department of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospitals, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig E.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacological Unit, Zealand University Hospital, Roskilde, Denmark"},{"name":"Department of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospitals, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik B.","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Mental Health Centre Sct Hans, Roskilde, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Werge","sequence":"additional","affiliation":[{"name":"Mental Health Centre Sct Hans, Roskilde, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi D.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Copenhagen Research Center for Mental Health\u2013CORE, Roskilde, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Skov","family":"Kaas-Hansen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacological Unit, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merete","family":"Nordentoft","sequence":"additional","affiliation":[{"name":"Copenhagen Research Center for Mental Health\u2013CORE, Roskilde, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"issue":"3","key":"zoi200893r1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/acps.2012.125.issue-3","article-title":"Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice.","volume":"125","author":"J\u00fcrgens","year":"2012","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"zoi200893r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2010.73","article-title":"Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.","volume":"11","author":"Fleeman","year":"2011","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"zoi200893r3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","article-title":"Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective cohort study.","volume":"6","author":"Jukic","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"zoi200893r4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/bcpt.2013.113.issue-4","article-title":"Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?","volume":"113","author":"Herbild","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"zoi200893r5","first-page":"1","article-title":"Pharmacogenomic testing for psychotropic medication selection: a systematic review of the Assurex GeneSight Psychotropic Test.","volume":"17","author":"Health Quality Ontario","year":"2017","journal-title":"Ont Health Technol Assess Ser"},{"issue":"6","key":"zoi200893r6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4088\/JCP.15r10583","article-title":"Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? a systematic review of clinical trials and cost-effectiveness studies.","volume":"78","author":"Rosenblat","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"zoi200893r7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/issn.0077-0094","article-title":"Methods for assessing positive and negative symptoms.","volume":"24","author":"Andreasen","year":"1990","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"zoi200893r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/acp.1987.76.issue-s334","article-title":"The UKU side effect rating scale\u2014a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"2","key":"zoi200893r9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/schbul\/20.2.297","article-title":"Rating of medication influences (ROMI) scale in schizophrenia.","volume":"20","author":"Weiden","year":"1994","journal-title":"Schizophr Bull"},{"issue":"8 Pt 1","key":"zoi200893r10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/clinchem\/46.8.1072","article-title":"Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR.","volume":"46","author":"Hersberger","year":"2000","journal-title":"Clin Chem"},{"issue":"1","key":"zoi200893r11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/0014-5793(96)00779-X","article-title":"Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.","volume":"392","author":"L\u00f8vlie","year":"1996","journal-title":"FEBS Lett"},{"issue":"1","key":"zoi200893r12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/JCP.0b013e31823f6b6a","article-title":"Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?","volume":"32","author":"J\u00fcrgens","year":"2012","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"zoi200893r13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"issue":"1","key":"zoi200893r14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations.","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet Med"},{"issue":"9","key":"zoi200893r15","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1517\/17425250903081738","article-title":"Implementation of CYP2D6 genotyping in psychiatry.","volume":"5","author":"Loovers","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"zoi200893r16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fgene.2012.00318","article-title":"Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine.","volume":"3","author":"Lee","year":"2013","journal-title":"Front Genet"},{"issue":"4","key":"zoi200893r17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/00031305.1993.10476000","article-title":"Interrater reliability with SPSS for Windows 5.0.","volume":"47","author":"MacLennan","year":"1993","journal-title":"Am Stat"},{"issue":"4","key":"zoi200893r19","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1534\/genetics.109.108977","article-title":"Exact tests for Hardy-Weinberg proportions.","volume":"183","author":"Engels","year":"2009","journal-title":"Genetics"},{"key":"zoi200893r20","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.99","article-title":"Using a pharmacogenomic algorithm to guide the treatment of depression.","volume":"2","author":"Hall-Flavin","year":"2012","journal-title":"Transl Psychiatry"},{"issue":"10","key":"zoi200893r21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/FPC.0b013e3283649b9a","article-title":"Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting.","volume":"23","author":"Hall-Flavin","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"zoi200893r22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12888-017-1412-1","article-title":"Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.","volume":"17","author":"P\u00e9rez","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"2","key":"zoi200893r23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.9758\/cpn.2015.13.2.150","article-title":"Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report.","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"89","key":"zoi200893r24","first-page":"219","article-title":"A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.","volume":"16","author":"Winner","year":"2013","journal-title":"Discov Med"},{"key":"zoi200893r25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4088\/JCP.v64n1116b","article-title":"Effectiveness of antidepressants: comparative remission rates.","volume":"64","author":"Thase","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"zoi200893r26","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"6","key":"zoi200893r27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2215-0366(16)00017-1","article-title":"Commercial pharmacogenetic-based decision-support tools in psychiatry.","volume":"3","author":"Bousman","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"zoi200893r28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bcp.2015.79.issue-2","article-title":"Addressing phenoconversion: the Achilles\u2019 heel of personalized medicine.","volume":"79","author":"Shah","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"zoi200893r29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol Psychiatry"},{"issue":"9","key":"zoi200893r30","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1373\/clinchem.2003.030825","article-title":"Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.","volume":"50","author":"Steimer","year":"2004","journal-title":"Clin Chem"},{"issue":"4","key":"zoi200893r33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/cpt.v103.4","article-title":"Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.","volume":"103","author":"Bank","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"zoi200893r34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.v13.1","article-title":"Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"12","key":"zoi200893r35","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"zoi200893r18","volume-title":"Modern Epidemiology","author":"Rothman","year":"2008"},{"key":"zoi200893r31","unstructured":"CPIC. Guidelines. Updated August 11, 2020. Accessed September 9, 2020. https:\/\/cpicpgx.org\/guidelines\/"},{"key":"zoi200893r32","unstructured":"U-PGx. Pharmacogenomics guidelines (DPWG). Accessed September 9, 2020. https:\/\/upgx.eu\/guidelines\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2773776\/jrgens_2020_oi_200893_1606772863.77336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T19:06:08Z","timestamp":1724007968000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2773776"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.27909","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,7]]}}}